Galli M G
Ann Ig. 1989 Jan-Apr;1(1-2):247-54.
Rubella vaccination has been introduced in USA in 1969: it was addressed to all the newborn and to women in childbearing age. In 1970 it was offered in Europe to schoolgirls aged 11-14 and to women of reproductive age. The purposes were identical--namely to eliminate the incidence of CRS--in spite of the different strategies adopted: in fact the American vaccination programme tried to reach this aim in eradicating the disease, while in Europe special attention was given to the possibility of reduce morbidity in childbearing age. After 20 years we can try to verify if these objects have been attained. Recent data (MMWR, 1987) show that rubella morbidity in USA has dropped considerably (incidence rate in 1966 = 24.3; in 1986 = 0.2) and incidence rate for CRS decreased accordingly from 0.90 (1969) to 0.32. Nevertheless we must underline that 47.5% of cases in USA from 1984 to 1986 were seen in person older than 20, and serologic studies have shown that infection susceptibility, in the postpuberal population, is the same that in prevaccinal era (10-20%). Many evaluation of efficacy of vaccinal strategies have been carried out in Europe, always showing a smaller number of women of reproductive age susceptible toward infection, together with a reduced probability of exposure during pregnancy. In European countries, were rubella vaccination has been offered only to women, morbidity has not changed appreciably. In Italy rubella vaccination has not been introduced at the same time and with the same extension in all regions: for this reason it is not possible to evaluate efficacy of this vaccination policy on a whole. Considering ISTAT data from 1971 to 1987 we can identify epidemic outbreaks in 1973, 1978, 1982 (of limited intensity) and 1984; practically every six years, as they took place before vaccination era; if we take into account case notified between 1971 and 1981 in the different age groups (table 1) we can see that the higher prevalence is always in the 6-13 years age group. Vaccination has not modified the epidemiologic trend of the disease. However, considering only the class toward whom vaccination was addressed from the beginning, that is women of reproductive age, that can have had the possibility to be vaccinated in prepuberal years at school or in another occasion, after serologic screening, in adult life, we can notice substantial differences in infection susceptibility in comparison with prevaccinal era, that was about 10-20% (Galli, 1982).(ABSTRACT TRUNCATED AT 400 WORDS)
风疹疫苗于1969年在美国推出:接种对象为所有新生儿和育龄妇女。1970年在欧洲,该疫苗面向11至14岁的女学生和育龄妇女提供。尽管采取了不同策略,但其目的是相同的——即消除先天性风疹综合征(CRS)的发病率:实际上,美国的疫苗接种计划试图通过根除该疾病来实现这一目标,而在欧洲,则特别关注降低育龄期发病率的可能性。20年后,我们可以尝试验证这些目标是否已经实现。最新数据(《发病率与死亡率周报》,1987年)显示,美国的风疹发病率大幅下降(1966年发病率为24.3;1986年为0.2),CRS的发病率也相应从0.90(1969年)降至0.32。然而,我们必须强调,1984年至1986年美国47.5%的病例发生在20岁以上人群中,血清学研究表明,青春期后人群的感染易感性与疫苗接种前时代相同(10 - 20%)。欧洲对疫苗接种策略的效果进行了多次评估,结果总是显示育龄期易感感染的女性数量减少,同时孕期接触感染的概率降低。在仅向女性提供风疹疫苗接种的欧洲国家,发病率没有明显变化。在意大利,风疹疫苗接种在所有地区并非同时且以相同范围推行:因此,无法整体评估这一疫苗接种政策的效果。考虑到意大利国家统计局1971年至1987年的数据,我们可以确定1973年、1978年、1982年(强度有限)和1984年有疫情爆发;实际上,就像疫苗接种时代之前一样,几乎每六年爆发一次;如果我们考虑1971年至1981年不同年龄组报告的病例(表1),我们可以看到发病率最高的始终是6至13岁年龄组。疫苗接种并未改变该疾病的流行病学趋势。然而,仅考虑从一开始就作为疫苗接种对象的人群,即育龄妇女,她们有可能在青春期前在学校或其他场合接种疫苗,或在成年后经过血清学筛查后接种,我们可以注意到与疫苗接种前时代相比,感染易感性存在显著差异,疫苗接种前时代约为10 - 20%(加利,1982年)。(摘要截选至400字)